1. Home
  2. |Insights
  3. |Litigation Note: Crowell & Moring Secures IP Victory for Apotex

Litigation Note: Crowell & Moring Secures IP Victory for Apotex

Firm News | less than 1 min read | 10.01.15

Washington, D.C. - October 1, 2015: Crowell & Moring represented Apotex in successfully challenging the validity of U.S. Patent No. 8,324,283 before the U.S. Patent and Trademark Office Patent Trial and Appeals Board (PTAB). Apotex, along with generic pharmaceutical companies Torrent Pharmaceuticals and Mylan Pharmaceuticals, petitioned the PTAB to invalidate the '283 patent related to oral formulations for the administration of the multiple sclerosis drug fingolimod, marketed by Novartis as Gilenya®. As a result, all claims of the '283 patent were found invalid by PTAB.

Insights

Firm News | 1 min read | 11.22.24

Crowell & Moring Represents Anitian in Successful $7M Series D Funding

San Francisco - November 22, 2024: Crowell & Moring advised Anitian, a leading provider of compliance automation solutions, on a $7 million Series D funding, led by Sageview Capital and with participation by Forgepoint Capital. This funding enables Anitian to accelerate the development of new innovations, including AI-driven automation features and an accredited Platform-as-a-Service (PaaS). Together, these features reduce the time and cost of achieving FedRAMP and CMMC compliance for Cloud Service Providers (CSPs) and the Defense Industrial Base (DIB). The most recent financing brings Anitian’s total funding to more than $50 million....

View All Insights